Generic Trintellix Availability

Trintellix is a brand name of vortioxetine, approved by the FDA in the following formulation(s):

TRINTELLIX (vortioxetine hydrobromide - tablet;oral)

• Manufacturer: TAKEDA PHARMS USA
  Approval date: September 30, 2013
  Strength(s): EQ 5MG BASE ^[RLD], EQ 10MG BASE ^[RLD], EQ 15MG BASE ^[RLD], EQ 20MG BASE ^[RLD]

Has a generic version of Trintellix been approved?

No. There is currently no therapeutically equivalent version of Trintellix available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trintellix. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Phenyl-piperazine derivatives as serotonin reuptake inhibitors
  Patent 7,144,884
  Issued: December 5, 2006
  Inventor(s): Ruhland; Thomas & Smith; Garrick Paul & Bang-Andersen; Benny & Puschl; Ask & Moltzen; Ejner Knud & Andersen; Kim
  Assignee(s): H. Lundbeck A/S
  The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder
  
  Patent expiration dates:
  • January 9, 2023
    
    ✓ 
    Patent use: METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Phenyl-piperazine derivatives as serotonin reuptake inhibitors
  Patent 8,476,279
  Issued: July 2, 2013
  Assignee(s): H. Lundbeck A/S
  The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.
  
  Patent expiration dates:
  • October 2, 2022
    
    ✓ 
    Patent use: METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
    ✓ 
    Drug product
• 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
  Patent 8,722,684
  Issued: May 13, 2014
  Assignee(s): H. Lundbeck A/S
  1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
  
  Patent expiration dates:
  • June 30, 2031
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
  Patent 8,969,355
  Issued: March 3, 2015
  Assignee(s): H. Lundbeck A/S
  This disclosure relates to a method of treating a disease selected from the group consisting of affective disorders, depression, major depressive disorder, anxiety, general anxiety disorder, social anxiety disorder, obsessive compulsive disorder, panic disorder, and panic attacks. The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to a patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.
  
  Patent expiration dates:
  • June 15, 2027
    
    ✓ 
    Patent use: METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
• 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
  Patent 9,227,946
  Issued: January 5, 2016
  Assignee(s): H. Lundbeck A/S
  1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
  
  Patent expiration dates:
  • June 15, 2027
    
    ✓ 
    Patent use: METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • September 30, 2018 - NEW CHEMICAL ENTITY